PATENT CLAIM ANALYSIS

Application Number: 16081818
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-05
Patent Classification: ["514", "04400A"]

Abstract:
Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

Claim (Index 7):
The compound of  claim 5 , wherein the oligonucleotide comprises a sequence selected from: (SEQ\u2003ID\u2003NO:\u200367) LNA\u20031: 5\u2032 AccAaaAGaaT\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200368) LNA\u20032: 5\u2032 TggCcATcaaT\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200369) LNA\u20033: 5\u2032 TagCAtActtA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200370) LNA\u20034: 5\u2032 CCAAAAGA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200371) LNA\u20035: 5\u2032 CATACTTA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200372) LNA\u20036: 5\u2032 CagaCaCGaCCaaAA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200373) LNA\u20037: 5\u2032 TAcTtaCTgaCagCC\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200374) LNA\u20038: 5\u2032 AGACacgaccaAAAG\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200375) LNA\u20039: 5\u2032 TACTtactgacaGCC\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200376) LNA9.2: 5\u2032 TACttactgacAGCC\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200377) LNA10: 5\u2032ACCaaaagAAT\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200378) LNA11: 5\u2032 TGGccatcAAT\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200379) LNA12: 5\u2032TAGcatacTTA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200380) LNA13: 5\u2032CgacCAaaAGaattC\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200381) LNA14: 5\u2032CGACcaaaagaATTC\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200382) LNA15: 5\u2032GaTGgCcATcaAttA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200383) LNA16: 5\u2032GATGgccatcaATTA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200384) LNA17: 5\u2032TcTAgCaTActTacT\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200385) LNA18: 5\u2032TCTAgcatactTACT\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200386) LNA19: 5\u2032GAAttcggatgGCCA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200387) LNA20: 5\u2032GGCCatcaattaGTG\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200388) LNA21: 5\u2032TTCGgatggccaTCA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200389) LNA22: 5\u2032AGCCagacagCGA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200390) LNA23: 5\u2032GACAgccagacaGCA\u20033\u2032;   (SEQ\u2003ID\u2003NO:\u200391) LNA\u20039.G74C: 5\u2032TACTtactgacaGTC\u20033\u2032; and   (SEQ\u2003ID\u2003NO:\u200392) LNA\u20039.T80C: 5\u2032TACTtaccgacaGCC\u20033\u2032; wherein capitalized letters denote LNA nucleotides and lowercase letters denote DNA nucleotides.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 96.0
- Lexical Diversity: 2.17188
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15203581', '15865364', '14699213', '13594611', '14332121']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6695684459924426
- 35 USC 102 Novelty (BERT): 0.5283678669711998
- Combined Prediction Score: 0.6554483880903184
- Mean Citation Score: 298.882436
- Max Citation Score: 305.1271700000001
- Similarity Product: 170.03761493927362

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test